Testosterone prodrug - Lipocine
Alternative Names: LPCN-1144Latest Information Update: 28 Dec 2024
At a glance
- Originator Lipocine
- Class Anabolic steroids; Androstenols; Antifibrotics; Hepatoprotectants; Hormonal replacements; Small molecules; Testosterone congeners
- Mechanism of Action Androgen receptor agonists; Testosterone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Non-alcoholic steatohepatitis
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
- No development reported Hepatic fibrosis
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Hepatic-fibrosis in USA (PO)
- 07 Nov 2024 Lipocine plans to request a Type C meeting with the FDA to discuss the clinical development plan for LPCN 1148
- 11 Apr 2024 Efficacy and adverse events data from a phase II trial in Non-alcoholic steatohepatitis released by Lipocine